Company: LENZ
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001815776-25-000071
Chunk: 295

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 295
---
 value$188,872 $46,309 $142,563 $— The following table presents the amortized cost and estimated fair market value of our cash equivalents and marketable securities as of the dates presented (in thousands):September 30, 2025Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesEstimated FairValueCash equivalents:Money market funds$24,735 $— $— $24,735 Marketable securities:Corporate debt securities$57,402 $63 $(2)$57,463 U.S. treasury securities49,669 105 (2)49,772 Commercial paper46,712 25 (4)46,733 U.S. government agency securities12,950 17 — 12,967 Asset-backed securities9,813 25 — 9,838 Totals$201,281 $235 $(8)$201,508 

17

December 31, 2024Amortized CostGrossUnrealizedGainsGrossUnrealizedLossesEstimated FairValueCash equivalents:Money market funds$17,693 $— $— $17,693 U.S. government securities999 — — 999 U.S. treasury securities997 — — 997 Marketable securities:Commercial paper$58,798 $56 $(31)$58,823 U.S. treasury securities46,231 80 (2)46,309 Corporate debt securities43,634 49 (14)43,669 U.S. government agency securities40,013 60 (2)40,071 Totals$208,365 $245 $(49)$208,561 The following table presents available-for-sale securities by contractual maturity date as of September 30, 2025 (in thousands):September 30, 2025Amortized CostEstimated Fair ValueDue in one year or less$150,531 $150,703 Due after one year26,015 26,070 Total$176,546 $176,773 As of September 30, 2025, twelve of the Company's marketable securities with a fair market value of $18.6 million were in an immaterial aggregate gross unrealized loss position due to the timing of their acquisition compared to their respective maturity date. These twelve marketable securities have